Patient Care Transitions in COPD: Improving Collaboration Between Inpatient and Outpatient Providers to Reduce Readmissions

Release Date: July 7, 2017
Expiration Date: July 7, 2018


Sleep Medicine and Lung
Health Consultants
Pittsburgh, Pennsylvania
Senior Staff Physician
Pittsburgh Critical Care Associates
Pittsburgh, Pennsylvania

B. Justin Krawitt, MD
Medical Director of Care
Management and
Clinical Documentation
Medical Center
Lebanon, New Hampshire
Assistant Professor of Medicine
Geisel School of Medicine
Dartmouth College
Hanover, New Hampshire

Program Overview

The burden and frequency of hospitalization for chronic obstructive pulmonary disease (COPD) remain high. Addressing this burden requires increased vigilance of changing COPD symptoms and risk factors for exacerbations and hospitalizations. It also requires that inpatient and outpatient healthcare providers evaluate patient status and provide therapies matched to individual patient needs. Gaps remain in healthcare providers’ ability to recognize personal risk factors in patients with COPD, as well as in collaboration between inpatient and outpatient healthcare providers. This program aims to address these gaps through education and review strategies that have been shown to be effective in reducing rates of readmission in patients with COPD.

Target Audience

This educational initiative has been designed for physicians, nurse practitioners, physician assistants, and nurse case managers involved in the management of COPD.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe long-term management strategies that may reduce COPD-related hospital readmissions
  • Review important comorbidities of COPD as part of a management strategy to reduce readmissions
  • Incorporate physical and cognitive assessments over the course of the inpatient-to-outpatient transition to determine the appropriate device for patients with COPD
  • Improve communication between inpatient and outpatient healthcare providers who manage patients with COPD to better coordinate care transitions

Directions to Learner

There are no fees for participating and receiving CME credit for this enduring activity. During the period of July 7, 2017 through July 7, 2018, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.



Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Credit Designation

Integrity Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest (COI)

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Consulting fees: Monaghan Medical, Nonin Medical, Philips Respironics, Sunovion Pharmaceuticals, Inc.
Speakers Bureau: Monaghan Medical, Philips Respironics, Sunovion Pharmaceuticals, Inc.

B. Justin Krawitt, MD
Consulting fees Sunovion Pharmaceuticals, Inc.

Patima Tanapat, PhD, has no real or apparent conflicts of interest to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sunovion Pharmaceuticals, Inc., do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc., and Sunovion Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Privacy Policy

When you participate in an online educational activity provided by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and...(continued)

Minimum System Requirements

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer is not recommended.

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Adobe® Flash® Player 10

Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

begin pretest


 Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from Sunovion Pharmaceuticals, Inc.